$3500 | Single User
$7000 | Site License
$10500 | Enterprise License

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Pipeline Review, H2 2016
[Lowest Price Guaranteed: $3,500]

Published by Global Markets Direct: 26 Oct 2016 | 20625 | In Stock
Related Topics: Drug , Protein

Introduction

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Pipeline Review, H2 2016’, provides in depth analysis on Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted pipeline therapeutics.

The report provides comprehensive information on the Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)

- The report reviews Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics and enlists all their major and minor projects

- The report assesses Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Pipeline Review, H2 2016

  • Table of Contents

    Table of Contents 2

    List of Tables 4

    List of Figures 4

    Introduction 5

    Global Markets Direct Report Coverage 5

    Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) Overview 6

    Therapeutics Development 7

    Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Products under Development by Stage of Development 7

    Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Products under Development by Therapy Area 8

    Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Products under Development by Indication 9

    Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Pipeline Products Glance 10

    Early Stage Products 10

    Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Products under Development by Companies 11

    Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Therapeutics Assessment 13

    Assessment by Monotherapy/Combination Products 13

    Assessment by Mechanism of Action 14

    Assessment by Route of Administration 15

    Assessment by Molecule Type 16

    Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Companies Involved in Therapeutics Development 17

    Mateon Therapeutics Inc 17

    Phelix Therapeutics, LLC 18

    Virobay Inc. 19

    Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Drug Profiles 20

    Drugs to Inhibit Cathepsin L for Infectious Diseases - Drug Profile 20

    Product Description 20

    Mechanism Of Action 20

    R&D Progress 20

    KGP-94 - Drug Profile 21

    Product Description 21

    Mechanism Of Action 21

    R&D Progress 21

    VBY-129 - Drug Profile 22

    Product Description 22

    Mechanism Of Action 22

    R&D Progress 22

    VBY-285 - Drug Profile 23

    Product Description 23

    Mechanism Of Action 23

    R&D Progress 23

    VBY-825 - Drug Profile 24

    Product Description 24

    Mechanism Of Action 24

    R&D Progress 24

    VBY-X - Drug Profile 25

    Product Description 25

    Mechanism Of Action 25

    R&D Progress 25

    Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Dormant Projects 26

    Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Featured News & Press Releases 27

    Apr 07, 2014: OXiGENE Announces Results of KGP94 Preclinical Studies at 2014 AACR Conference 27

    Mar 27, 2014: OXiGENE Announces Presentation of Preclinical Abstracts at 2014 AACR Conference 27

    Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model 28

    Appendix 30

    Methodology 30

    Coverage 30

    Secondary Research 30

    Primary Research 30

    Expert Panel Validation 30

    Contact Us 30

    Disclaimer 31

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

20625 | GMDHC0600TDB

Number of Pages

31

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Pipeline Review, H2 2017
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Pipeline Review, H2 2017Summary...
30 Sep 2017 by Global Markets Direct USD $3,500 More Info
Cathepsin K/S Inhibitor -Pipeline Insights, 2017
DelveInsight’s, “Cathepsin K/S Inhibitor-Mechanism of action Insights, 2017”, report provides compre...
01 Sep 2017 by Delve Insight USD $1,250 More Info
Cathepsin K Inhibitor -Pipeline Insights, 2017
DelveInsight’s, “Cathepsin K Inhibitor-Mechanism of action Insights, 2017”, report provides comprehe...
01 Sep 2017 by Delve Insight USD $1,250 More Info
Cathepsin S inhibitor -Pipeline Insights, 2017
DelveInsight’s, “Cathepsin S inhibitor-Mechanism of action Insights, 2017”, report provides comprehe...
01 Sep 2017 by Delve Insight USD $1,250 More Info
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Pipeline Review, H2 2017
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Pipeline Review, ...
18 Jul 2017 by Global Markets Direct USD $3,500 More Info
Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) - Pipeline Review, H1 2017
Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin...
20 Jun 2017 by Global Markets Direct USD $3,500 More Info
Cathepsin K Inhibitors -Pipeline Insights, 2017
DelveInsight’s, “Cathepsin K Inhibitors-Pipeline Insights, 2017”, report provides in depth insights ...
30 May 2017 by Delve Insight USD $1,250 More Info
Cathepsin S inhibitor -Pipeline Insights, 2017
DelveInsight’s, “Cathepsin S inhibitor-Pipeline Insights, 2017”, report provides in depth insights o...
30 May 2017 by Delve Insight USD $1,250 More Info
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Pipeline Review, H2 2016
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Pipeline Review, ...
28 Dec 2016 by Global Markets Direct USD $3,500 More Info
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Pipeline Review, H2 2016
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Pipeline Review, H2 2016Summary...
26 Oct 2016 by Global Markets Direct USD $3,500 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Pipeline Review, H2 2016 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...